Biotech News
Jaguar Health Reports 2025 Financials
jaguarhealth.gcs-web.com2026-05-06 15:20 EST
Net revenue increase of 5% in Q4 2025 vs. Q3 2025 Jaguar received an up-front payment of $16Mof non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi ® and Canalevia ® -CA1 - Jaguar's commercialized crofelemer drugs - with an additional $2 million due